Triglav Investments D.O.O. Acquires 21,900 Shares of Johnson & Johnson $JNJ

Triglav Investments D.O.O. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 36.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 82,800 shares of the company’s stock after acquiring an additional 21,900 shares during the period. Johnson & Johnson comprises 1.0% of Triglav Investments D.O.O.’s holdings, making the stock its 23rd largest holding. Triglav Investments D.O.O.’s holdings in Johnson & Johnson were worth $15,353,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in Johnson & Johnson by 25.8% during the 3rd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 411,513 shares of the company’s stock worth $76,303,000 after buying an additional 84,355 shares during the period. Howe & Rusling Inc. raised its position in shares of Johnson & Johnson by 10.4% during the third quarter. Howe & Rusling Inc. now owns 21,470 shares of the company’s stock worth $3,981,000 after acquiring an additional 2,020 shares during the last quarter. Optimize Financial Inc bought a new stake in Johnson & Johnson in the third quarter valued at approximately $441,000. Auxano Advisors LLC increased its position in Johnson & Johnson by 3.4% during the 3rd quarter. Auxano Advisors LLC now owns 16,166 shares of the company’s stock valued at $2,998,000 after purchasing an additional 531 shares during the period. Finally, Savant Capital LLC increased its position in Johnson & Johnson by 5.8% during the 3rd quarter. Savant Capital LLC now owns 255,620 shares of the company’s stock valued at $47,397,000 after purchasing an additional 14,076 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $237.66 on Friday. The business’s fifty day simple moving average is $212.87 and its 200 day simple moving average is $193.33. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $239.58. The firm has a market capitalization of $572.60 billion, a P/E ratio of 21.51, a price-to-earnings-growth ratio of 2.28 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, hitting analysts’ consensus estimates of $2.46. The company had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on JNJ. Raymond James Financial upped their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Leerink Partners upped their price target on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research report on Thursday, January 22nd. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Citigroup boosted their price target on Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Finally, Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.